Anti-allergic esters, acetal ethers, thioethers and nitrogen substituted derivatives of bicyclic compounds

ABSTRACT

Esters, acetal ethers, thioethers and nitrogen substituted derivatives of certain bicyclic compounds are disclosed which are useful as anti-allergic, anti-inflammatory and/or cytoprotective agents and in treatment of hyperproliferative skin disease. Pharmaceutical compositions and methods of treatment employing such compounds are also disclosed.

The present application is a continuation-in-part of copending U.S.application Ser. No. 760,196 filed July 29, 1985 now U.S. Pat. No.4,684,727.

BACKGROUND OF THE INVENTION

The present invention relates to esters, acetal ethers, thioethers andnitrogen substituted derivatives of certain bicyclic compounds and topharmaceutical compositions and methods of use employing such compounds.

An article by Bowman et al. entitled "The Synthesis of SomeDialkylamino-2-quinolones," Journal of the Chemical Society, pp.1350-1353 (1964), discloses certain1-alkyl-3-dialkylamino-4-hydroxy-2-quinolones. Mentioned in this articleare 3-dimethylamino-4-hydroxy-1-phenyl-2-quinolone and1-benzyl-3-dimethylamino-4-hydroxy-2-quinolone. No utility is mentionedin the article for such compounds.

Certain other 3-amino substituted quinolones are disclosed in Kappe etal., Monatshefte fur Chemie, 99, pp. 2157-2166 (1968); Merchant et al.,Curr. Sci., 49(1), pp. 20-21 (1980); and Wittmann et al. Z.Naturforsch., B: Anorg. Chem., Org. Chem., 33B(12), pp. 1540-1546(1978).

SUMMARY OF THE INVENTION

The present invention involves a compound having the structural formulaIa or Ib ##STR1## a pharmaceutically acceptable salt or a solvatethereof, wherein:

W and X may be the same or different and each independently represents--CH═ or --N═;

Z₁ and Z₂ are the same or different and each independently represents Oor S;

R¹, R², R³, R⁴ and R⁵ are the same or different and each may beindependently selected from the group consisting of H, alkyl having from1 to 12 carbon atoms, alkenyl having from 3 to 8 carbon atoms, alkynylhaving from 3 to 8 carbon atoms, alkoxyalkyl having from 1 to 6 carbonatoms in the alkoxy portion and from 2 to 6 atoms in the alkyl portionthereof, hydroxyalkyl having from 2 to 8 carbon atoms, cycloalkyl havingfrom 3 to 8 carbon atoms, acyloxyalkyl having from 1 to 6 carbon atomsin the acyloxy portion and from 2 to 8 carbon atoms in the alkyl portionthereof, and --R⁷ --CO₂ R⁰ wherein R⁷ represents an alkylene grouphaving from 1 to 6 carbon atoms and R⁰ represents hydrogen or an alkylgroup having from 1 to 6 carbon atoms, with the provisos that the OH ofthe hydroxyalkyl group and the acyloxy of the acyloxyalkyl group are notjoined to the same carbon atom as another heteroatom and that, when R¹,R² and/or R³ are alkenyl or alkynyl, there is at least one carbon-carbonsingle bond between the nitrogen atom and the carbon-carbon double ortriple bond;

in addition, one of R¹ or R² can be an aryl group or a heterocyclicgroup, either of which can be substituted with one to three substituentsY as defined below:

in further addition, any two of R¹, R² and R³ can be joined together torepresent a ring which can contain from 2 to 8 carbon atoms, said ringoptionally containing a --O--, --S-- and/or --NR⁴ -- heteroatomic group(wherein R⁴ is as defined above) and/or optionally containing acarbon-carbon double bond, and said ring optionally being substitutedwith one to three additional substituents R⁸ which substituents may bethe same or different and are each independently selected from OH withthe proviso that OH is not on a carbon already joined to a hetero atom,--O-acyl having from 1 to 6 carbon atoms, hydroxyalkyl having from 1 to8 carbon atoms, alkoxyalkyl having from 1 to 6 carbon atoms in eachalkyl portion thereof, alkyl having from 1 to 6 carbon atoms, alkenylhaving from 3 to 8 carbon atoms, alkynyl having from 3 to 8 carbonatoms, --COOR⁹ wherein R⁹ represents H, alkyl or aryl, or any two R⁸substituent groups may represent a hydrocarbon ring having from 4 to 8total carbon atoms;

in still further addition, all three of R¹, R² and R³ can be joinedtogether to represent a polycyclic hydrocarbon ring, which polycyclicring can optionally be substituted by one to three substituent groups R⁸as defined above;

R⁶ represents --CO--R¹⁰, --CS--OR¹⁷, --CS--NR¹⁵ R¹⁶, --C(R¹¹)₂ --OR¹²,--C(R¹¹)₂ --SR¹² or --C(R¹¹)₂ --NR¹² R¹³ ;

R¹⁰ represents aryl, --R¹⁴, aromatic heterocyclic, --OR¹⁴ or --NR¹⁵ R¹⁶;

each R¹¹ represents H, alkyl, --CCl₃, --COOR⁹ or aryl;

R¹² represents --R¹⁴ (preferably alkyl having from 8 to 12 carbon atoms,--CO--R¹³ or --CS--R¹⁷ ;

R¹³ represents H, alkyl or aryl;

R¹⁴ represents alkyl of from 1 to 12 carbon atoms;

R¹⁵ and R¹⁶ each independently represents H, alkyl or aryl, or R¹⁵ andR¹⁶ together represent a divalent polymethylene group of from 4 to 6carbon atoms, said polymethylene group being optionally substituted witha carboxy group or alkyl ester thereof;

R¹⁷ represents --R¹⁴ or aryl;

m is an integer of from 0 to 3;

n is an integer of from 0 to 2;

Q represents an aryl or an aromatic heterocyclic group which canoptionally be substituted with 1 to 3 substituents Y as defined below;

each Y substituent is independently selected from the group consistingof hydroxy, alkyl having from 1 to 6 carbon atoms, halogen, NO₂, alkoxyhaving from 1 to 6 carbon atoms, trifluoromethyl, cyano, cycloalkylhaving from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbonatoms, alkynyloxy having from 3 to 6 carbon atoms, hydroxyalkyl havingfrom 1 to 6 carbon atoms, --S(O)_(n) --R¹⁸ (wherein R¹⁸ represents alkylhaving from 1 to 6 carbon atoms and n is as defined above), --SO₂ NH₂,--CO--R¹⁹ (wherein R¹⁹ represents OH, --NH--R¹⁸ or --O--R¹⁸, where R¹⁸is as defined above), --O--B--COR¹⁹ (wherein B represents an alkylenegroup having from 1 to 4 carbon atoms and R¹⁹ is as defined above),--NH₂, --NHCHO, --NH--CO--R¹⁹ (wherein R¹⁹ is as defined above, with theproviso that it is not hydroxy), --NH--COCF₃, --NH--SO₂ R¹⁸ (wherein R¹⁸is as defined above, and --NHSO₂ CF₃ ;

A is a pharmaceutically acceptable counterion.

A preferred subgenus of compounds is represented by those compounds inwhich at least one of W and X is N. More preferably, W is CH and X is N.Moreover, at least one of Z₁ and Z₂ is preferably O and m and n arepreferably zero.

An additional preferred subgenus of compounds is represented by thestructural formula II ##STR2## wherein R¹, R², R⁶, Q, Z₁ and Z₂ are asdefined above. Preferably, at least one of Z₁ and Z₂ L is O. Inaddition, Q is preferably an aryl group such as a phenyl group, whichmay be optionally substituted with one to three Y groups, morepreferably, one or two Y groups.

Suitable Z₂ -esters include simple alkyl esters, aryl esters, aralkylesters, aromatic heterocyclic esters such as furyl or pyridinyl esters,carbamates such as N,N-dialkylcarbamates, proline carbamate esters, etc.Examples of suitable Z₂ -ester groups include --O(CO)CH₃, --O(CO)C₂ H₅,--O(CO)phenyl, --O(CO)-p -tolyl, ##STR3## --O(CO)N(C₂ H₅)₂,--O(CO)C(CH₃)₃, ##STR4## etc. Examples of suitable Z₂ -acetal estersinclude those wherein both R¹¹ groups are H and where R¹² is C₈₋₁₂ alkylsuch as n-octyl or R¹² is CO-- alkyl such as (CO)C(CH₃)₃. Examples ofsuitable thioethers and nitrogen containing compounds include --CH₂--S-alkyl wherein the alkyl group contains 8-12 carbon atoms, e.g.,n-octyl, and --CH₂ --NHalkyl wherein the alkyl group contains from 1-12carbon atoms, e.g., n-octyl.

The invention also involves (1) pharmaceutical compositions comprising acompound of formula Ia or Ib as defined above in combination with apharmaceutically acceptable carrier and (2) methods of using thecompounds of formula Ia or Ib as defined above to treat allergicreactions, inflammation, peptic ulcers or hyperproliferative skindisease by administering such a compound to a mammal in an amounteffective for such purpose.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention may be prepared by reacting acompound of structural formula III with a compound of formula IV:##STR5## wherein R¹, R², R³, R⁴, R⁵, R⁶, Q, X, Y, W, Z₁, Z₂, m and n areas defined above and L is an appropriate leaving group such as halo,e.g., chloro. For example, suitable reagents include an appropriateanhydride or acid halide to prepare the ester or a compound LC(R¹¹)₂OR¹², LC(R¹¹)₂ SR¹² or LC(R¹¹)₂ -NR¹² R¹³ to prepare the acetal ethers,thioethers or nitrogen substituted compounds. Exemplary reagents includeacetyl chloride, pivaloyl chloride, N,N-diethyl carbamoyl chloride,methoxymethyl chloride, pivaloyloxymethyl chloride,N-(chloromethyl)benzamide, chloromethyl phenyl sulfide, etc. Preferably,the reaction is performed in a basic solvent such as pyridine or2,6-lutidine (with or without the addition of dimethylaminopyridine(DMAP) or in a neutral solvent in the presence of an organic base suchas triethylamine. Sometimes, it is desirable to add a halide exchangereagent such as NaI or KBr to the reaction mixture to produce a morereactive leaving group.

The compounds of formula III above can be prepared from a compound ofstructural formula V: ##STR6## wherein R⁴, R⁵, Q, X, Y, W, Z₁, Z₂, m andn are as defined above and L₁ is a substituent known to those skilled inthe art as a "leaving group."

Treatment of a compound of the formula V above with the amine compoundof the formula VI ##STR7## (wherein R¹, R² and R³ are as defined above)with heat in a suitable solvent, such as pyridine, dimethyl formamide,hexamethyl phosphoramide, 2,6-lutidine, dimethyl acetamide and the like,results in formation of the desired product of formula III. Thereaction, depending upon the reactants chosen, can be performed attemperatures of about 60° C. up to the reflux temperature of theparticular solvent.

For purposes of the invention, a "leaving group" is defined as asubstituent which may be displaced and carry a negative charge.Representative examples of suitable leaving groups include chloride,bromide, iodide, trifluoroacetoxy, methanesulfonyloxy,trifluoromethanesulfonyloxy, p-toluene-sulfonyloxy, --I--Ar, and thelike. A preferred leaving group is bromide.

The compound of formula VI above is generally a secondary amine ortertiary amine, i.e., one in which at most one of the groups R¹, R² orR³ is hydrogen. Such materials are readily obtainable eithercommercially or by methods well known to one of ordinary skill in theart.

The intrmediates of formula V above are either known or can be preparedfrom corresponding 3-unsubstituted derivatives which are disclosed, forexample, in U.S. Pat. No. 4,492,702, the disclosure of which isincorporated herein by reference. For example, a compound of the formulaVII ##STR8## (wherein Q, R⁴, R⁵, Y, W, X, n and m are as defined hereinand R is any convenient alkyl or aryl group) may be reacted with acompound of structural formula VIII

    CH.sub.3 CO.sub.2 R                                        VIII

(wherein R is again, for example, an alkyl or aryl group) to directlyproduce the compounds of the formula IX ##STR9## This reaction ispreferably accomplished by contacting the two reactants VII and VIII inthe presence of a base such as a metal alkoxide, e.g., potassiumtertiary butoxide or the like, at an elevated temperature, e.g., 60° toabout 160° C., for a sufficient time until the reaction is substantiallycompleted. The reaction is preferably conducted in an inert atmospheresuch as nitrogen. Alternatively, the reaction may be conducted in thepresence of a non-reactive solvent such as toluene, xylene, etc.

The compounds of formula IX above can be reacted with a suitable agentto provide the leaving group in the three position on the ring. Forexample, direct bromination of the compound of formula IX above willprovide a compound of formula V above where L¹ equals Br. As anotherexample, reaction of the compound of IX above with iodosobenzene resultsin the formation of a compound of formula V where L is --I--Ph.

The compounds of formula III wherein R³ is H (i.e., formula IIIa below)can also be prepared by reacting a compound of formula VII with acompound of formula X in the presence of a base: ##STR10## wherein R andR' each independently represents alkyl or aryl. Suitable bases include,for example, NaH, potassium t-butoxide, etc.

Alternatively, a compound of formula VII may be reacted with a compoundof formula XI or XII in the presence of a base (or an epoxide with thecompound of the formula XI): ##STR11## wherein L¹ and L² may be the sameor different and each represents a leaving group such as halo and Rrepresents alkyl or aryl. The compound of formula XIII is then reactedwith a compound of formula VI to form an intermediate of formula XIVwhich may be converted to the product IIIa by use of a suitable basesuch as Li--N(Si(CH₃)₃)₂, sodium methoxide or potassium t-butoxide:##STR12##

The compounds having structural formula III or IIIa above wherein Z₁ andZ₂ are oxygen may be converted to the corresponding compounds wherein Z₁and/or Z₂ are sulfur by known methods. For example, treatment withLawesson's Reagent[2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide] inhot toluene will effect this conversion. These sulfur analogs can thenbe used to prepare the compounds of formula Ia or Ib wherein Z₁ and/orZ₂ is S by the general methods discussed above. The isomeric andtautomeric forms can be purified by chromatography of the reactionmixture.

When utilized herein and in the appended claims the below listed termsare defined as follows:

halogen--fluorine, chlorine, bromine and iodine;

alkyl and alkoxy--comprise straight and branched carbon chains and,unless otherwise specified, contain from 1 to 6 carbon atoms;

alkenyloxy--comprise straight and branched carbon chains and, unlessotherwise specified, have from 3 to 8 carbon atoms and contain a carbonto carbon double bond;

alkynyloxy--comprise straight and branched carbon chains and, unlessotherwise specified, have from 3 to 8 carbon atoms and contain a carbonto carbon triple bond;

aryl--a carbocyclic group containing at least one benzene ring, with thearyl groups containing from 6 to 15 carbon atoms, preferably beingphenyl or phenyl substituted with 1 to 3 Y groups, e.g., phenyl,naphthyl, indenyl, indanyl, 4-chlorophenyl, 4-fluorophenyl,2,4,6-trimethylphenyl etc.;

aromatic heterocyclic--cyclic groups having at least one O, S and/or Nheteroatom interrupting the ring structure and having a sufficientnumber of unsaturated carbon to carbon bonds, nitrogen to carbon bonds,etc., to provide aromatic character, with the aromatic heterocyclicgroups containing from 2 to 14 carbon atoms, e.g., pyridyl, furyl,thienyl, thiazolyl, imidazolyl, pyrimidinyl, pyrazinyl, pyridazinyl,1,2,4-triazinyl, benzofuranyl, indolyl, pyrazolyl, oxazolyl, etc. Manytimes such heterocyclic groups can be bonded via various positions onthe ring and all such variations are contemplated, e.g. 2- or 3-furanyl,2-, 3- or 4-pyridyl, etc.

The compounds of the invention may contain a --(CR⁴ R⁵)_(m) --substituent wherein each R⁴ group and each R⁵ group may varyindependently. Thus, for example, when m equals 2 the following patternsof substitution (wherein hydrogen and CH₃ are used to represent anysubstituent, R⁴ or R⁵) are contemplated: --C(CH₃)₂ CH₂ --, --CH₂ C(CH₃)₂--, --CH₂ CH(CH₃)--, --CH(CH₃)CH₂ --, --(C(CH₃)H)₂ -- and the like. Inaddition when m equals 3, substituents such as --C(CH₃)₂ CH(C₂ H₅)--CH₂--, --CH(CH₃)--CH₂ --CH(C₂ H₅)--, and --CH₂ --CH(i--C₃ H₇)CH(C₂ H₅)--are also contemplated.

The R¹, R² and R³ groups on the amino nitrogen in the compounds of theinvention can be the same or different. In some instances as notedabove, two of R¹, R² and R³ may together represent a heterocyclic ringsystem with the nitrogen of the amino group being part of such ring,e.g., a monocyclic ring. Examples of suitable --NR¹ R² or --NR¹ R² R³groups include a primary amino group NH₂ ; secondary amino groups suchas --NH(CH₃), --NH(--CH₂ --CH═CH₂), --NH(phenyl), --NH(4-pyridyl), etc.;tertiary amino groups such as --N(CH₃)₂, --N(CH₂ CO₂ H [C(CH₂ OH)₃ ],etc.; quaternary amino groups such as --N(CH₃)₃, --N(CH₃)₂ (phenyl)etc.; and tertiary and quaternary heterocyclic amino groups containingthe nitrogen atom in the heterocyclic ring such as pyrrolidinyl,1-methyl pyrrolidinyl, piperidinyl, 1-methyl piperidinyl, etc.

As noted above, the compounds of the invention may include one to threeY substituents on the bicyclic ring system. Also, the Q group mayinclude one or two Y substituents. In cases where there is more than onesuch Y substituent, they may be the same or different. Thus, compoundshaving combinations of different Y substituents are contemplated withinthe scope of the invention. Examples of suitable Y substituents includeOH, methyl, chloro, bromo, methoxy, cyclohexyl, allyloxy, 2-propynyloxy,hydroxyethyl, methylthio, methylsulfonyl, carboxy, acetoxy,N-methylaminocarbonyl, acetoxymethoxy, acetamido, methylsulfonamido andthe like.

The compounds of the invention may be in the form of pharmaceuticallyacceptable salts, i.e., pharmaceutically acceptable acid addition orbasic salts. Examples of suitable acid addition salts include thechloride (from hydrochloric acid), methyl sulfate (from methyl sulfuricacid), sulfate (from sulfuric acid) and bromide.

The compounds of the invention of formula I can exist in unsolvated aswell as solvated forms, including hydrated forms, e.g., a hemihydrate.In general, the solvated forms, with pharmaceutically acceptablesolvents such as water, ethanol and the like are equivalent to theunsolvated forms for purposes of the invention.

Certain compounds of the invention may exist in isomeric and tautomericforms. The invention contemplates all such isomers and tautomers--theisomers both in pure form and in admixture, including racemic mixtures.

The compounds of the invention may be employed as anti-allergy agents inthe treatment of, for example, asthma, allergic or seasonal rhinitis,and/or chronic bronchitis.

The anti-allergy method of this invention is identified by tests whichmeasure a compound's inhibition of anaphylactic bronchospam insensitized guinea pigs having antigen induced broncho-constriction.

In one such test procedure, male Hartley guinea pigs (250-300 g) aresensitized with 5 mg ovalbumin injected i.p. and 5 mg injected s.c. in 1ml saline on day 1 and 5 mg ovalbumin injected i.p. on day 4. Thesensitized animals are used 3-4 weeks later at which time they weigh450-500 g.

The sensitized guinea pigs are fasted overnight and the followingmorning are anesthetized with 0.9 ml/kg i.p. of dialurethane (0.1 g/mdiallybarbituric acid, 0.4 g/ml ethylurea and 0.4 g/ml urethane). Thetrachea are cannulated and the animals are ventilated by a Harvardrodent respirator at 50 strokes/minute with a stroke volume of 5 ml. Aside arm to the tracheal cannula is connected to a Harvard pressuretransducer to obtain a continuous measure of intratracheal pressurewhich is recorded on a Harvard polygraph. The jugular vein is cannulatedfor the i.v. administration of substances. The animals are challengedwith antigen (0.5% ovalbumin) as an aerosol generated from a DeVilbissModel 65 ultrasonic nebulizer and delivered through the tracheal cannulafor 30 seconds. Bronchoconstriction is measured as the peak increase inintratracheal pressure occuring within 5 minutes after antigenchallenge.

The sensitized guinea pigs are injected i.v. with 1 mg/kg propranolol, 5mg/kg indomethacin and 2 mg/kg mepyramine given together in a volume of1 ml/kg. Fifteen minutes later the animals are challenged with nebulizedovalbumin. Test compounds are administered orally 2 or 8 hours beforechallenge with ovalbumin. Suppression of anaphylactic bronchospasm isexpressed as a percent inhibition of the peak increase in intratrachealpressure by comparison to a vehicle-treated control group. Results forrepresentative compounds of the invention are shown in Table I below:

                  TABLE I                                                         ______________________________________                                         ##STR13##                                                                                Dose      % Inhibition After                                      R.sup.6       (mg/kg p.o.)                                                                              2 hr      8 hr.                                     ______________________________________                                        CH.sub.3CO    10           87*      --                                        (CH.sub.3).sub.3 CCO                                                                        5           48        49                                         ##STR14##    5           30         0                                        (C.sub.2 H.sub.5).sub.2 NCO                                                                 5           48        32                                        ______________________________________                                         *This measurement was made in a 21/2 day multipledosing regimen version o     the assay.                                                               

The results demonstrate that the compounds of the invention areeffective inhibitors of allergic reactions and provide a relatively longduration of action.

The compounds also inhibit allergen-induced histamine release fromguinea pig and human sensitized tissue. The compounds are effectivenon-adrenergic, non-anticholinergic, antianaphylactic agents. Whenadministered orally they are active at doses from about 0.1 to 10 mg/kgof body weight; when administered parenterally, e.g., intravenously, thecompounds are active at dosages of from about 0.05 to 5 mg/kg bodyweight, when administered by inhalation (aerosol or nebulizer) thecompounds are active at dosages of about 0.25 to 5 mg per puff, one tofour puffs may be taken every 4 hours.

The compounds of this invention are also useful for the treatment ofinflammation. Thus, they are useful in the treatment of arthritis,bursitis, tendonitis, gout and other inflammatory conditions. Theanti-inflammatory use of the compounds of the present invention may bedemonstrated by the Reversed Passive Arthus Reaction (RPAR) Synovitistechnique as set forth below using male Lewis rats (obtained fromCharles River Breeding Laboratories) weighing 200-250 grams and the RPARPaw technique as also described below. The potency of the compounds isdetermined using indomethacin as the standard. On the basis of the testresults, an oral dosage range of about 5 milligrams per kilogram of bodyweight per day to about 50 milligrams per kilogram of body weight perday in divided doses taken at about 4 hour intervals is recommended.

The dosage to be administered and the route of administration dependsupon the particular compound used, the age and general health of thepatient and the severity of the inflammatory condition. Thus, the doseultimately decided upon must be left to the judgment of a trainedhealth-care practitioner.

RPAR Synovitis Technique

A Lewis rat is dosed orally with drug or placebo one hour prior tointravenous administration of 2.28 mg of bovine serum albumin (BSA) in0.2 cc of pyrogen-free saline followed by the intraarticular injectionof 0.54 mg of rabbit anti-BSA antibody in 0.03 cc of pyrogen-free salineinto one knee joint. The contralateral knee is injected with 0.03 cc ofpyrogen free saline. All injections are made with the animal under lightether anesthesia. Three hours later the rat is again dosed orally withdrug or placebo. All drug doses are split. That is, one-half of the doseis administered before lesion induction and one-half is administeredafter lesion induction.

The following morning (about 17 hours after lesion induction) the rat iskilled and both knee joints are exposed. The subpatellar areolar tissuewith attendant synovium is excised and weighed. Differences between theweight of antibody and saline injected knees are considered to representthe inflammatory response for each animal (delta synovial weight).Differences in delta synovial weight between lesion controls anddrug-treated rats are evaluated for statistical significance with ananalysis of variance. Relative potencies are determined with a linearregression analysis.

Reversed Passive Arthus Response (RPAR) PAW Animals, Materials andMethods

Male Lewis inbred albino rats weighing 180-200 grams obtained fromCharles River Breeding Laboratories are used in these experiments. Therats are housed 3 animals/cage and food and water are allowed adlibitum. The animals are numbered 1-3 in each cage and color marked foridentification purposes.

CL Drug and Reagent Preparation

All reagents and drugs are prepared just prior to the study.Crystallized and lyophilized bovine serum albumin (BSA), available fromSigma Chemical Company, is solubilized without shaking in cold, sterile,pyrogen-free saline (10 mg/ml). Lyophilized anti-bovine serum albumin(IgG fraction), obtained from Cappel Laboratories, is suspended insterile distilled water and diluted with cold, pyrogen-free saline (PFS)just prior to use. The final concentration of anti-bovine serum albuminis 0.5 mg/ml of PFS. Both BSA and anti-BSA solutions are iced duringuse. Drugs are suspended or solubilized in an aqueous solution of methylcellulose (MC) with an homogenizer just prior to administration.

Drug Administration and Induction of Inflammation

Groups of animals (6/group) are dosed with drug in MC by gavage oncedaily for 3 days. The last dose is administered one hour prior tosensitization with BSA. Controls are given MC alone and a drug-standardis usually included in each assay for verification purposes. Drugs areprepared and diluted so as to provide a dose for a 200 gram animal whichis equivalent to the mg/kg dose for each experiment. Thus each ratreceives an oral dose in a volume of approximately 2.0 cc. One hourafter the last dose the animals are lightly anesthetized with ether and"sensitized" by injection of 0.2 ml of PFS containing 1.0 mg of BSA intothe penile vein. One hour later, the animals are "challenged" in theright rear paw with subplantar injections of 0.2 ml of PFS containing0.1 mg of anti-BSA. Immediately after the subplantar injection, theright paw is dipped (up to the lateral maleolus) into the mercury wellof a plethysmograph. The volume of mercury displaced is converted toweight and recorded. This value is considered to be the control readingfor the animal. Paw volumes are subsequently recorded with aplethysmograph during the development of the inflammation at 2 and 4hours post-challenge.

Results

Results are expressed by the change in paw volume (Δpaw volume) from thecontrol reading for each animal to that recorded 2 and 4 hourspost-challenge. All drug treated groups are compared to the MC controlfor significant differences with an analysis of variance. Differencesfrom control in drug-treated groups are expressed as percent change fromcontrol. For example, the compounds4-(2,2-dimethylpropionyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-oneand4-(N,N-diethylcarbamoyl)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-onegiven at an oral dose of 25 mg/kg, inhibited the paw edema by 28% and54%, respectively, at 2 hours and by 5% and 17%, respectively, at 4hours.

The compounds of this invention are also useful in the treatment ofpeptic ulcers. They display chemotherapeutic activity which enables themto relieve the symptoms of peptic ulcer disease, stress ulceration, andpromote healing of gastric and/or duodenal ulcers. The antiulceractivity of the compounds of this invention is identified by tests whichmeasure the cytoprotective effect in rats. The compounds are also usefulas conjunctive therapeutic agents for coadministration with suchantiinflammatory/analgesic agents as aspirin, indomethacin,phenylbutazone, ibuprofen, naproxen, tolmetin and other agents. Thecompounds of this invention prevent the untoward side effects ofirritation and damage to the gastrointestinal tract caused by suchagents.

The compounds of this invention are evaluated for their antiulceractivity characterstics by standard biological testing procedures suchas the indomethacin-induced ulcer and/or ethanol-induced ulcer assaysdetailed below:

Indomethacin-Induced Ulcer Assay

Male Charles River CD rats (250-260 g) are fasted overnight. The testcompound is administered orally in methyl cellulose vehicle (2 ml/kg) tothe animals one hour prior to indomethacin 10 mg/kg p.o. The rats aresacrificed by CO₂ asphyxiation 4 hours after indomethacin. The stomachsare examined under a magnifying glass for lesions (Chiu et al., Arch.Int. Pharmacodyn. Ther., 270, 128 (1984).

Ethanol-Induced Ulcer Assay

Male Charles River CD rats weighing 250°-260 g are fasted and deprivedof water for 20 hours before the experiments. The test compound,homogenized in aqueous methyl cellulose vehicle, is administered orally30 minutes prior to oral administration of 1 ml of absolute ethanol. Onehour after ethanol the rats are sacrificed and the stomachs excised. Thestomachs are opened through the greater curvature and the length of eachlinear hemorrhagic lesion induced by ethanol is measured and summatedfor each stomach. Results are expressed as the mean lesion length (mm)per rat (±SE). The data are analyzed by Duncan's multiple range test anda P value of <0.05 is considered significant.

The compounds of this invention are found to be effective at doses ofabout 0.05-50 mg/kg of body weight per day. Preferably the total dosagesare administered in 2-4 divided doses per day.

When administered parenterally, e.g. intravenously, the compounds areadministered at a dosage range of about 0.01-10 mg/kg of body weight insingle or multiple daily doses.

To treat peptic ulcer disease, and prevent and treat drug-inducedgastric ulceration, the active compounds of this invention can beadminstered in unit dosage forms such as tablets, capsules, pills,powders, granules, sterile parenteral solutions or suspensions,suppositories, mechanical delivery devices, e.g. transdermal, and thelike.

The compounds of formula Ia and Ib are useful in the treatment ofhyperproliferative skin-disease, e.g., psoriasis, which utility may bedemonstrated by the Arachidonic Acid Mouse Ear Test described below.

Arachidonic Acid Mouse Ear Test, Materials and Methods

Charles River, female, CD, (SD) BR mice, 6 weeks old, are caged 8/groupand allowed to acclimiate 1-3 weeks prior to use.

Arachidonic acid (AA) is dissolved in reagent grade acetone (2 mg/0.01ml) and stored at -20° C. for a maximum of 1 week prior to use.Inflammatory reactions are induced by applying 10 μl of AA to bothsurfaces of one ear (4 mg total).

Test drugs are dissolved in either reagent grade acetone or aqueousethanol (only if insoluble in acetone) at the same doses selected byOpas et al., Fed. Proc. 43, Abstract 2983, p. 1927 (1984) and Young etal., J. Invest. Dematol. 82, pp 367-371 (1984). These doses are employedto ensure maximum responses and to overcome any difference in topicalabsorption which could occur with any drug applied in an aqueous ethanolvehicle. The test drug is applied 30 minutes prior to challenge with AA.

The severity of the inflammation is measured as a function of increasedear weight. A 6 mm punch biopsy is removed 1 hour after AA challenge andweighed to the nearest 0.1 mg. Mean ± standard error and all possiblecomparisons are made via Duncan's Multiple Range Statistic.

When administered for the treatment of hyperproliferative skin disease,the compounds of formula Ia or Ib may be administered topically, orally,rectally or parenterally. When administered topically, the amount ofcompound administered varies widely with the amount of skin beingtreated, as well as with the concentration of active ingredient appliedto the affected area. When administered orally, the compounds of formulaIa or Ib are effective for the treatment of hyperproliferative skindisease at daily doses ranging from about 0.1 mg/kg to about 100 mg/kg,preferably from about 5 mg/kg to about 50 mg/kg, which may beadministered in divided doses. When administered rectally, the compoundsof formula Ia or Ib may be administered in daily doses ranging fromabout 0.1 mg/kg to about 100 mg/kg. When administered parenterally, thecompounds of formula Ia or Ib are effective for the treatment ofhyperproliferative skin disease in daily doses ranging from about 0.1mg/kg body weight to about 10 mg/kg body weight which may beadministered in divided doses.

As a result of the topical administration of a compound of formula Ia orIb, a remission of the symptoms of the psoriatic patient, in most cases,can be expected. Thus, one affected by psoriasis can expect a decreasein scaling, erythema, size of the plaques, pruritus and other symptomsassociated with psoriasis. The dosage of medicament and the length oftime required for successfully treating each individual psoriaticpatient may vary, but those skilled in the art of medicine will be ableto recognize these variations and adjust the course of therapyaccordingly.

Included within the invention are preparations for topical applicationto the skin whereby the compounds having structural formula Ia or Ib areeffective in the treatment and control of skin diseases characterized byrapid rates of call proliferation and/or abnormal cell proliferation,e.g. psoriasis.

In a preferred method of carrying out the invention, a pharmaceuticalformulation comprising a compound of formula Ia or Ib together with anon-toxic, pharmaceutically acceptable topical carrier, usually inconcentrations in the range of from about 0.001 percent to about 10percent, preferably from about 0.1 percent to about 5 percent, isapplied several times daily to the affected skin until the condition hasimproved. Topical applications may then be continued at less frequentintervals (e.g. once a day) to control mitosis in order to preventreturn of severe disease conditions.

For preparing pharmaceutical compositions from the compounds describedby this invention, inert, pharmaceutically acceptable carriers can beeither solid or liquid. Solid form preparations include powders,tablets, dispersible granules, capsules, cachets and suppositories. Asolid carrier can be one or more substances which may also act asdiluents, flavoring agents, solubilizers, lubricants, suspending agents,binders or tablet disintegrating agents; it can also be an encapsulatingmaterial. In powders, the carrier is a finely divided solid which is inadmixture with the finely divided active compound. In the tablet theactive compound is mixed with carrier having the necessary bindingproperties in suitable proportions and compacted in the shape and sizedesired. The powders and tablets preferably contain from 5 or 10 toabout 70 percent of the active ingredient. Suitable solid carriers aremagnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin,dextrin, starch, gelatin, tragacanth, methylcellulose, sodiumcarboxymethyl-cellulose, a low melting wax, cocoa butter and the like.The term "preparation" is intended to include the formulation of theactive compound with encapsulating material as carrier providing acapsule in which the active component (with or without other carriers)is surrounded by carrier, which is thus in associated with it.Similarly, cachets are included. Tablets, powders, cachets and capsulescan be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax such as a mixture offatty acid glycerides or cocoa butter is first melted, and the activeingredient is dispersed homogeneously therein as by stirring. The moltenhomogeneous mixture is then poured into convenient sized molds, allowedto cool and thereby solidify.

Liquid form preparations include solutions, suspensions and emulsions.As an example may be mentioned water or water-propylene glycol solutionsfor parenteral injection. Liquid preparations can also be formulated insolution in aqueous polyethylene glycol solution. Aqueous solutionssuitable for oral use can be prepared by adding the active component inwater and adding suitable colorants, flavors, stabilizing, sweetening,solubilizing and thickening agents as desired. Aqueous suspensionssuitable for oral use can be made by dispersing the finely dividedactive component in water with viscous material, i.e., natural orsynthetic gums, resins, methylcellulose, sodium carboxymethylcelluloseand other well-known suspending agents.

Also included are solid form preparations which are intended to beconverted, shortly before use, to liquid form preparations for eitheroral or parenteral administration. Such liquid forms include solutions,suspensions and emulsions. These particular solid form preparations aremost conveniently provided in unit dose form and as such as used toprovide a single liquid dosage unit. Alternatively, sufficient solid maybe provided so that after conversion to liquid form, multiple individualliquid doses may be obtained by measuring predetermined volumes of theliquid form preparation as with a syringe, teaspoon or other volumetriccontainer. When multiple liquid doses are so prepared, it is preferredto maintain the unused portion of said liquid doses at low temperature(i.e., under refrigeration) in order to retard possible decomposition.The solid form preparations intended to be converted to liquid form maycontain, in addition to the active material, flavorants, colorants,stabilizers, buffers, artificial and natural sweeteners, dispersants,thickeners, solubilizing agents and the like. The solvent utilized forpreparing the liquid form preparation may be water, isotonic water,ethanol, glycerine, propylene glycol and the like as well as mixturesthereof. Naturally, the solvent utilized will be chosen with regard tothe route of administration, for example, liquid preparations containinglarge amounts of ethanol are not suitable for parenteral use.

The compounds of the invention may also be deliverable transdermally.The transdermal compositions can take the form of creams, lotions and/oremulsions and can be included in a transdermal patch of the matrix orreservoir type as are conventional in the art for this purpose.

Preferably, the pharmaceutical preparation is in unit dosage form. Insuch form, the preparation is subdivided into unit doses containingappropriate quantities of the active component. The unit dosage form canbe a packaged preparation, the package containing discrete quantities ofpreparation, for example, packeted tablets, capsules and powders invials or ampoules. The unit dosage form can also be a capsule, cachet ortablet itself or it can be the appropriate number of any of these inpackaged form.

The quantity of active compound in a unit dose of preparation may bevaried or adjusted from 1 mg to 100 mg according to the particularapplication and to the potency of the active ingredient. Thecompositions can, if desired, also contain other therapeutic agents.

The dosages may be varied depending upon the requirements of thepatient, the severity of the condition being trated and the particularcompound being employed. Determination of the proper dosage for aparticular situation is within the skill of the art. Generally,treatment is initiated with smaller dosages which are less than theoptimum dose of the compound. Thereafter, the dosage is increased bysmall increments until the optimum effect under the circumstances isreached. For convenience, the total daily dosage may be divided andadministered in portions during the day if desired.

The following examples are intended to illustrate, but not to limit, thepresent invention.

PREPARATIVE EXAMPLE 1 Preparation of4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one

A mixture of methyl-2-phenylamino nicotinate (75.2 g), n-butylacetate(700 mL) and potassium tertbutoxide (148 g) was stirred and heatedgradually to reflux. The mixture was refluxed for 16 hours, after whichtime it was cooled and poured into water (7L) with stirring. Theresulting mixture was acidified to pH 5 with concentrated HCl when awhite solid precipitated. The product was filtered off and air dried.The solid product was then suspended in hexane (3L), triturated,filtered and washed with fresh hexane. This purification process wasrepeated using ether (1.5L). The product was dried to yield 48 g of thedesired product, m.p. 312°-314° C.

By a similar procedure, using modifications well known to one skilled inthe art, the starting materials

ethyl-2-(pyrazinylamino)-nicotinate,

ethyl-2-(4-pyrimidinylamino)-nicotinate,

ethyl-2-(3-(1,2,4-triazinylamino))-nicotinate, and

ethyl-2-(2-thienylmethylamino)-nicotinate

can to converted to

4-hydroxy-1-(2-pyrazinyl)-1,8-naphthyridin-2(1H)-one,

4-hydroxy-1-(4-pyrimidinyl)-1,8-naphthyridin-2(1H)-one,

4-hydroxy-1-(3-(1,2,4-triazinyl))-1,8-naphthyridin-2(1H)-one, and

4-hydroxy-1-(2-thienylmethyl)-1,8-naphthyridin-2(1H)-one, respectively.

PREPARATIVE EXAMPLE 2 Preparation of3-bromo-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one

To a suspension of 4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one (1 g)in CH₂ Cl₂ (20 mL) was added, dropwise and with stirring, a solution ofbromine (0.7 g) in CH₂ Cl₂ (5 mL). The mixture was stirred at roomtemperature overnight, after which time the product was filtered off,dried in air and recrystallized from acetonitrile to yield 0.87 g of theproduct, m.p. 280° C.

By employing a similar procedure to that described in Example 2 aboveusing simple modifications based on practices well-known to one skilledin the art, the compounds

4-hydroxy-1-(2-pyrazinyl)-1,8-naphthyridin-2(1H)-one,

4-hydroxy-1-(4-pyrimidinyl)-1,8-naphthyridin-2(1H)-one,

4-hydroxy-1-(3-(1,2,4-triazinyl))-1,8-naphthyridin-2(1H)-one, and

4-hydroxy-1-(2-thienylmethyl)-1,8-naphthyridin-2(1H)-one

can be converted to

3-bromo-4-hydroxy-1-(2-pyrazinyl)-1,8-naphthyridin-2(1H)-one,

3-bromo-4-hydroxy-1-(4-pyrimidinyl)-1,8-naphthyridin-2(1H)-one,

3-bromo-4-hydroxy-1-(3-(1,2,4-triazinyl))-1,8-naphthyridin-2(1H)-one,and

3-bromo-4-hydroxy-1-(2-thienylmethyl)-1,8-naphthyridin-2(1H)-one,respectively.

PREPARATIVE EXAMPLE 3 Preparation of1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-1-methyl-pyrrolidiniumhydroxide, inner salt

In dry pyridine (30 mL),3-bromo-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one (10 g) wassuspended. N-methyl pyrrolidine (20 mL) was added to the suspension. Themixture was heated to 95°-100° C. with stirring, and was kept there forabout 33 hours. The product was evaporated under high vacuum to providea dark oil. This oil was slurried with 200 mL of CH₃ CN(40): H₂ O(60):CH₃ CO₂ H(1) and filtered. The solid residue on the filter was rinsedwith water and the filtrate was evaporated to remove most of the CH₃ CN.Reversed phase chromatography through an E. Merck RP-8 LoBar column,eluting with increasing concentrations of CH₃ CN in H₂ O (containing 1%CH₃ CO₂ H) gave a moderately pure product which was subjected to asecond chromatographic separation using the same conditions as above.Fractions containing the product were combined and evaporated to yield asolid which was recrystallized from CH₂ Cl₂ /isopropanol to yield thedesired product, m.p. 245°-250° C.

PREPARATIVE EXAMPLE 4 Preparation of1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-1-methyl-pyrrolidiniumchloride

1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-1-methyl-pyrrolidiniumhydroxide, inner salt (0.1 g) was dissolved in 0.1N-HCl solution (38mL). The solution was concentrated under high vacuum to provide an oilwhich crystallized on the addition of isopropanol. The solid wasfiltered off and washed with isopropanol to yield the desiredhydrochloride salt, m.p. 195° C.

PREPARATIVE EXAMPLE 5 Preparation of1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-pyrrolidiniumhydroxide, inner salt

A solution of 3-bromo-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one (2g) in a mixture of pyrrolidine (10 mL) and DMF (5 mL) was stirred andheated at 100° C. for 2 days. The resulting mixture was then cooled,diluted with CH₂ Cl₂ (100 mL) and filtered. The solid was trituratedwith hot CHCl₃, filtered, and dried to yield the desired product, m.p.282°-284° C.

Some of the product was purified by (1) dissolving in a minimum volumeof 2,2,2-trifluoroethanol and (2) precipitating by addition of 4 volumesof methanol. The pure product charred and decomposed when heated aboveabout 285° C.

PREPARATIVE EXAMPLE 6 Preparation of1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-4-hydroxy-piperidiniumhydroxide, inner salt

A solution of 3-bromo-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one (1g) in a mixture of 2,6-lutidine (5 mL) and 4-hydroxy-piperidine (3.12 g)was heated at 100° C. for 32 hours. The lutidine was removed byevaporation under high vacuum. The residue was dissolved in CH₃CN(20):H₂ O(80):CH₃ CO₂ H(1) and separated by reversed phase preparativeHPLC (Whatman Magnum 40 with Partisil 40/ODS-3). The fractionscontaining the desired product were combined and evaporated to yield apartially crystalline material which was recrystallized from isopropanolto yield the desired product, m.p. 256°-258° C.

The following compounds were also prepared by the techniques similar tothose described above:

1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)quinuclidiniumhydroxide, inner salt, hemihydrate, m.p. 290° C.

1-methyl-1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-morpholiniumhydroxide, inner salt, hemihydrate, m.p. 248°-249° C.

1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-piperidiniumhydroxide, inner salt, hemihydrate, m.p. 261°-263° C. (decomp.).

1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-2-hydroxymethylpiperidinium hydroxide, inner salt, hemihydrate, m.p. 135°-138° C.

By employing procedures similar to those described above in PreparativeExamples 3, 4, 5 and 6 with simple modifications well known to oneskilled in the art, the compounds

3-bromo-4-hydroxy-1-(2-pyrazinyl)-1,8-naphthyridin-2(1H)-one,

3-bromo-4-hydroxy-1-(4-pyrimidinyl)-1,8-naphthyridin-2(1H)-one,

3-bromo-1-(3-chlorophenyl)-4-hydroxy-1,8-naphthyridin-2(1H)-one,

3-bromo-4-hydroxy-1-(3-(1,2,4-triazinyl))-1,8-naphthyridin-2(1H)-one,and

3-bromo-4-hydroxy-1-(2-thienylmethyl)-1,8-naphthyridin-2(1H)-one

can be converted to

1-[1,2-dihydro-4-hydroxy-2-oxo-1-(2-pyrazinyl)-1,8-naphthyridin-3-yl]-1-methyl-pyrrolidiniumhydroxide, inner salt,

1-[1,2-dihydro-4-hydroxy-2-oxo-1-(4-pyrimidinyl)-1,8-naphthyridin-3-yl]-1-methylpiperidiniumhydroxide, inner salt,

1-[1-(3-chlorophenyl)-1,2-dihydro-4-hydroxy-2-oxo-1,8-naphthyridin-3-yl]-1-methyl-pyrrolidiniumhydroxide, inner salt, or1-[1-(3-chlorophenyl)-1,2-dihydroxy-2-oxo-1,8-naphthyridin-3-yl]-piperidiniumhydroxide, inner salt, m.p. 258.5°-261° C.,

1-[1,2-dihydro-4-hydroxy-2-oxo-1-(3-(1,2,4-triazinyl))-1,8-naphthyridin-3-yl]-pyrrolidiniumhydroxide, inner salt, and

1-[1,2-dihydro-4-hydroxy-2-oxo-1-(2-thienylmethyl)-1,8-naphthyridin-3-yl]-piperidiniumhydroxide, inner salt, respectively.

PREPARATIVE EXAMPLE 7 Preparation of1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyrindin-3-yl)-pyrrolidiniumhydroxide, inner salt

Step A: To a stirred solution of 25.45 g (0.11M) ofmethyl-2-phenylamino-nicotinate in 160 mL of t-butyl methyl ether(tBuOMe) (dried over 3 A° sieves) heated to 50° (under N₂) 19.5 mL(2.2×0.11M) of chloroacetylchloride followed by 31 mL (4×0.11M) ofpropylene oxide was added. The reaction mixture was heated at 50° C. for1.5 hours and then 300 mL tBuOMe was added. This solution (cooled toroom temperature) was washed with 200 mL H₂ O containing 9.37 g (0.11M)of NaHCO₃ followed by 30 mL of saturated aqueous NaCl solution. At thisstage the product that crystallized out was dissolved in 100 mL CH₂ Cl₂and this CH₂ Cl₂ was mixed with tBuOMe solution. The solution, as is,was used for the next reaction.

Step B: To the above solution at room temperature under N₂, 37.2 mL(4×0.11M) of pyrrolidine was added and this solution was gently refluxedovernight. 9.3 mL (0.11M) of pyrrolidine was added, and the reaction wasrefluxed for an additional two hours. This mixture was diluted with 600mL tBuOME and washed with 300 mL H₂ O and the aqueous layers were backextracted with 200 mL tBuOMe. The combined organic (tBuOMe) layer waswashed with 150 mL saturated aqueous NaCl soln., dried over anhydrousNa₂ SO₄, and then concentrated in vacuum (oil pump vacuum) to 64.6 g ofa crude brown semisolid, which was the methyl ester of2-[[1-pyrrolidinylacetyl]phenylamino]-3-pyridine carboxylic acid.

Step C: The solid from step B above was suspended in 600 mL of cold (0°C.) tBuOMe (dried over 3 A° sieves) under N₂. To this cold stirredmixture, 27.5 g (2.2×0.11M) potassium t-butoxide was added, the reactionmixture was stirred for 1 hour, and then it was quenched with 15 mL(2.4×0.11M) of glacial acetic acid.

The stirred reaction mixture was allowed to attain room temperature andthen 350 mL H₂ O was added to it. The resultant solid was filtered,washed with tBuOMe, H₂ O, a small amount of CH₂ Cl₂, acetone, and thenair dried to obtain 27.09 g of the white product1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)pyrrolidiniumhydroxide, inner salt. The crude product was crystallized from 300 mLCH₃ OH+16 mL conc. H₂ SO₄ at 50° C.+3 g carbon; filtered, diluted with575 mL H₂ O, cooled to 0° C. and filtered; and draft oven dried at 60°C. for about 18 hours to give 22.2 g (82%) of crystallized whiteproduct.

EXAMPLE 1 Preparation of4-(4-methylbenzoyloxy)-1-phenyl-3(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one

A mixture of1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-pyrrolidiniumhydroxide, inner salt (3.0 g) and triethylamine (1.88 g) in CH₂ Cl₂ (100mL) was stirred for 1 hour at room temperature. p-Toluoyl chloride (1.79g) was added and the mixture was stirred at room temperature for about24 hours.

The product was poured into water (200 mL) and the pH was adjusted toabout 6 with acetic acid. The organic layer was separated, the aqueouslayer was extracted with ethyl acetate, and the organic layers werecombined, dried (Na₂ SO₄), filtered and evaporated to a solid which wasrecrystallized from isopropanol to yield the desired product, 2.07 g(50%), m.p. 216°-217° C.

EXAMPLE 2 Preparation of4-acetyloxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one

A mixture of1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-pyrrolidiniumhydroxide, inner salt (3 g) and triethylamine (1.41 g) in CH₂ Cl₂ (50mL) was stirred at room temperature in an atmosphere of nitrogen. Acetylchloride (1.09 g) was added dropwise and stirring was continued for atotal of about 20-24 hours. The product was poured into water (200 mL)and the pH was adjusted to 7 with 10% KOH solution. The organic layerwas separated and dried (Na₂ SO₄). The dry solution was filtered andevaporated to a solid which was recrystallized from isopropanol to yieldthe desired product, 2.17 g (67%) m.p. 197°-200° C.

EXAMPLE 3 Preparation of4-(2,2-dimethylpropionyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one

A mixure of1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-pyrrolidiniumhydroxide, inner salt (3 g) and triethylamine (1.88 g) in CH₂ Cl₂ wasstirred under N₂ for about 1 hour at room temperature. Trimethylacetylchloride (1.4 g) was added and stirring was continued for about a totalof 20 hours.

The product was poured into ice/water and the pH was adjusted to 5 withacetic acid. The aqueous phase was extracted with ethyl acetate, thecombined organic layers were dried (MgSO₄), filtered and evaporated to asolid which was crystallized from isopropanol to yield the desiredproduct, 2.75 g (66%) m.p. 163°-165° C.

EXAMPLE 4 Preparation of4-(N,N-diethylcarbamoyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one

A mixture of1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-pyrrolidiniumhydroxide, inner salt (3 g), triethylamine (1.88 g), anddiethylcarbamoyl chloride (1.57 g) in dry pyridine (50 mL) was stirredovernight at room temperature in an N₂ atmosphere. Some startingmaterial remained so dimethylformamide (50 mL),1,8-diazabicyclo[5.4.0]undec7-ene (DBU) (2.83 g), and diethylcarbamoylchloride (1.57 g) were added and the mixture was heated at 80° C. for0.5 hour. The reaction mixture was then poured over ice and the pH wasadjusted to about 6 with acetic acid. The resulting solution wasextracted three times with ethyl acetate. The organic extracts werecombined, dried (Na₂ SO₄), filtered and evaporated to a solid which wasrecrystallized from isopropanol to yield the desired product, 2.03 g(54%), m.p. 158°-160° C.

EXAMPLE 5 Preparation of4-(N,N-dimethylcarbamoyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one

To a suspension of1-(1,2-dihydro-4-hydroxyo-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-pyrrolidiniumhydroxide, inner salt (5.0 g) in dry pyridine (80 mL) and an N₂atmosphere, was added DBU (4.71 g) and dimethylcarbamoyl chloride (2.08g). The mixture was heated to 80° C. for 0.5 hour after which it waspoured into ice/water. The pH was adjusted to 6 with acetic acid. Theorganic layer was separated and the aqueous layer was extracted threetimes with ethyl acetate (200 mL). The combined organic layers weredried (Na₂ SO₄), filtered and evaporated to a solid. This material wassuspended in ether (1 L) and to it was added, with stirring, 1.5equivalent of methanesulfonic acid in ether (500 mL). After 1 hour ofvigorous stirring the solid product was filtered off, washed with etherand recrystallized from isopropanol to yield the salt of the desiredproduct, 5.05 g.

This material was suspended in water and aqueous NaHCO₃ solution wasadded until the pH of the water was about 6. The product was filteredoff and dried to provide the desired product in 46% yield, m.p.218°-220° C.

While the present invention has been described in conjunction with thespecific embodiments set forth above, many alternatives, modificationsand variations thereof will be apparent to those of ordinary skill inthe art. All such alternatives, modifications and variations areintended to fall within the spirit and scope of the present invention.

We claim:
 1. A compound having the structural formula Ia or Ib ##STR15##a pharmaceutically acceptable salt or a solvate thereof, wherein: W andX may be the same or different and each independently represents --CH═or --N═;Z₁ and Z₂ are the same or different and each independentlyrepresents O or S; R¹, R², R³, R⁴ and R⁵ are the same or different andeach independently represents H, alkyl having from 1 to 12 carbon atoms,alkenyl having from 3 to 8 carbon atoms, alkynyl having from 3 to 8carbon atoms, alkoxyalkyl having from 1 to 6 carbon atoms in the alkoxyportion and from 2 to 6 atoms in the alkyl portion thereof, hydroxyalkylhaving from 2 to 8 carbon atoms, cycloalkyl having from 3 to 8 carbonatoms, acyloxyalkyl having from 1 to 6 carbon atoms in the acyloxyportion and from 2 to 8 carbon atoms in the alkyl portion thereof, and--R⁷ --CO₂ R⁰ wherein R⁷ represents an alkylene group having from 1 to 6carbon atoms and R⁰ represents hydrogen or an alkyl group having from 1to 6 carbon atoms, with the provisos that the OH of the hydroxyalkylgroup and the acyloxy of the acyloxyalkyl group are not joined to thesame carbon atom as another heteroatom and that, when at least one ofR¹, R² and R³ is alkenyl or alkynyl, there is at least one carbon-carbonsingle bond between the nitrogen atom and the carbon-carbon double ortriple bond; in addition, one of R¹ or R² can be aryl having from 6 to15 carbon atoms which can be substituted with one to three substituentsY as defined below; in further addition, any two of R¹, R² and R³ can bejoined together to represent a moiety when taken together with the N towhich they are attached respresents a ring which contains from 2 to 8carbon atoms, said ring optionally containing in addition a --O--, --S--and/or --NR⁴ -- wherein R⁴ is as defined above, and optionallycontaining a carbon-carbon double bond, and said ring optionally beingsubstituted with one to three additional substituents R⁸ whichsubstituents may be the same or different and are each independtlyselected from OH with the proviso that OH is not on a carbon alreadyjoined to a hetero atom, --O--acyl having from 1 to 6 carbon atoms,hydroxyalkyl having from 1 to 8 carbon atoms, alkoxyalkyl having from 1to 6 carbon atoms in each alkyl portion thereof, alkyl having from 1 to6 carbon atoms, alkenyl having from 3 to 8 carbon atoms, alkynyl havingfrom 3 to 8 carbon atoms, --COOR⁹ wherein R⁹ represents H, alkyl having1 to 6 carbon atoms or aryl having from 6 to 15 carbon atoms, or any twoR⁸ substituent groups may represent a hydrocarbon ring having from 4 to8 total carbon atoms; in still further addition, all three of R¹, R² andR³ can be joined together to represent when taken together with the N towhich they are attached a polycyclic hydrocarbon ring, which polycyclicring can optionally be substituted by one to three substituent groups R⁸as defined above; R⁶ represents --CO--R¹⁰, --CS--OR¹⁷, --CS--NR¹⁵ R¹⁶,--C(R¹¹)₂ -- OR¹², --C(R¹¹)₂ --SR¹² or --C(R¹¹)₂ --NR¹² R¹³ ; R¹⁰represents aryl having from 6 to 15 carbon atoms, --R¹⁴, aromaticheterocyclic having from 2 to 14 carbon atoms and at least one O, Sand/or N in the ring structure, --OR¹⁴ or --NR¹⁵ R¹⁶ ; each R¹¹represents H, alkyl having from 1 to 6 carbon atoms, --CCl₃, --COOR⁹ oraryl having from 6 to 15 carbon atoms; R¹² represents --R¹⁴, --CO--R¹³or --CS--R¹⁷ ; R¹³ represents H, alkyl having 1 to 6 carbon atoms oraryl having from 6 to 15 carbon atoms; R¹⁴ represents alkyl having from1 to 12 carbon atoms; R¹⁵ and R¹⁶ each independently represents H, alkylhaving 1 to 6 carbon atoms or aryl having from 6 to 15 carbon atoms, orR¹⁵ and R¹⁶ taken together represent a divalent polymethylene group offrom 4 to 6 carbon atoms, said polymethylene group being optionallysubstituted with a carboxy group or alkyl ester thereof; R¹⁷ represents--R¹⁴ or aryl having from 6 to 15 carbon atoms; m is an integer of from0 to 3; n is an integer of from 0 to 2; Q represents aryl having from 6to 15 carbon atoms or an aromatic heterocyclic group having from 2 to 14carbon atoms and at least one O, S and/or N in the ring structure, whicharomatic heterocyclic group can optionally be substituted with from 1 to3 substituents Y as defined below; each Y substituent is independentlyhydroxy, alkyl having from 1 to 6 carbon atoms, halogen, NO₂, alkoxyhaving from 1 to 6 carbon atoms, trifluoromethyl, cyano, cycloalkylhaving from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbonatoms, alkynyloxy having from 3 to 6 carbon atoms, hydroxyalkyl havingfrom 1 to 6 carbon atoms, --S(O)_(n) --R¹⁸ wherein R¹⁸ represents alkylhaving from 1 to 6 carbon atoms and n is as defined above, --SO₂ NH₂,--CO--R¹⁹ wherein R¹⁹ represents OH, --NH-- R¹⁸ or --O--R¹⁸, where R¹⁸is as defined above, --O--B--COR¹⁹ wherein B represents an alkylenegroup having from 1 to 4 carbon atoms and R¹⁹ is as defined above,--NH₂, --NHCHO, --NH--CO--R¹⁹ wherein R¹⁹ is as defind above, with theproviso that it is not hydroxy, --NH--COCF₃, --NH--SO₂ R¹⁸ wherein R¹⁸is as defined above, or --NHSO₂ CF₃, and A is a pharmaceuticallyacceptable counterion.
 2. A compound according to claim 1, wherein atleast one of W and X is --N═.
 3. A compound according to claim 1,wherein X is N and W is --CH═.
 4. A compound according to claim 3,wherein at least one of Z₁ and Z₂ is O.
 5. A compound according to claim4, wherein Z₁ and Z₂ both are O.
 6. A compound according to claim 5,wherein n is zero.
 7. A compound according to claim 6, wherein m iszero.
 8. A compound according to claim 7, wherein Q is an aryl group,which may optionally be substituted with one to three Y groups.
 9. Acompound according to claim 8, wherein Q is an aryl group, which mayoptionally be substituted with one or two Y groups.
 10. A compoundaccording to claim 1, selectedfrom:4-(4-methylbenzoyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one;4-acetyloxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one;4-(2,2-dimethylpropionyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one;4-(N,Ndiethylcarbamoyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one;4-(N,N-dimethylcarbamoyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one;or a pharmaceutically acceptable salt or solvate of such a compund. 11.A compound according to claim 1 whichis4-acetyloxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one ora pharmaceutically acceptable salt or solvate thereof.
 12. A compoundaccording to claim 1 whichis4-(2,2-dimethylpropionyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-oneor a pharmaceutically acceptable salt or solvate thereof.
 13. Apharmaceutical composition which comprises an antiallergic,antiinflammatory, cytoprotective or anti-hyperproliferative skin diseaseeffective amount of a compound having structural formula I as defined inclaim 1 in combination with a pharmaceutically acceptable carrier.
 14. Amethod for treating allergic reactions in a mammal which comprisesadministering an anti-allergic effective amount of a compound of formulaI as defined in claim 1 to said mammal.
 15. A method for treatinginflammation in a mammal which comprises administering ananti-inflammatory effective amount of a compound of formula I as definedin claim 1 to said mammal.
 16. A method for treating peptic ulcers in amammal which comprises administering a cytoprotective effective amountof a compound of formula I as defined in claim 1 to said mammal.
 17. Amethod for treating a mammal suffering from hyperproliferative skindisease which comprises administering an effective amount of a compoundhaving structural formula I as defined in claim 1 to said mammal.
 18. Apharmaceutical composition according to claim 13, wherein the compoundof formula I is4-acetyloxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one or apharmaceutically acceptable salt or solvate thereof.
 19. Apharmaceutical composition according to claim 13, wherein the compoundof formula I is 4-(2,2-dimethylpropionyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one ora pharmaceutically acceptable salt or solvate thereof.
 20. A methodaccording to claim 14, wherein the compound of formula I is4-acetyloxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one or apharmaceutically acceptable salt or solvate thereof.
 21. A methodaccording to claim 14, wherein the compound of formula I is4-(2,2-dimethylpropionyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one ora pharmaceutically acceptable salt or solvate thereof.
 22. A methodaccording to claim 15, wherein the compound of formula I is4-acetyloxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one or apharmaceutically acceptable salt or solvate thereof.
 23. A methodaccording to claim 15, wherein the compound of formula I is4-(2,2-dimethylpropionyloxy)-1-phenyl-3-(-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one or apharmaceutically acceptable salt or solvate thereof.
 24. A methodaccording to claim 16, wherein the compound of formula I is4-acetyloxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one or apharmaceutically acceptable salt or solvate thereof.
 25. A methodaccording to claim 16, wherein the compound of formula I is4-(2,2-dimethylpropionyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one ora pharmaceutically acceptable salt or solvate thereof.
 26. A methodaccording to claim 17, wherein the compound of formula I is4-acetyloxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one or apharmaceutically acceptable salt or solvate thereof.
 27. A methodaccording to claim 17, wherein the compound of formula I is4-(2,2-dimethylpropionyloxy)-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one ora pharmaceutically acceptable salt or solvate thereof.